Draft biological evaluations for Atrazine, Simazine, and Propazine
In a letter to the EPA, CropLife America provides comment on the Draft National Level Listed Species Biological Evaluations for Atrazine, Simazine, and Propazine produced by the EPA via an Executive Summary, Policy Considerations, Technical Comments, and Conclusions.
Re: Comments on the Draft Biological Evaluations for Atrazine, Simazine, and Propazine, EPA-HQ-OPP- 2020-0514; 85 Fed. Reg. 71071 (November 6, 2020)
Dear Ms. Perry:
Established in 1933, CropLife America (CLA) represents the developers, manufacturers, formulators, and distributors of pesticides and plant science solutions for agriculture and pest management in the United States. CLA represents the interests of its registrant member companies by, among other things, monitoring legislation, federal agency regulations and actions, and litigation that impact the crop protection and pest control industries and participating in such actions when appropriate. CLA’s member companies produce, sell, and distribute virtually all the crop protection and biotechnology products used by American farmers.
CropLife America (CLA) appreciates the opportunity to comment on the Draft National Level Listed Species Biological Evaluations for Atrazine, Simazine, and Propazine (the Draft Triazine BEs) produced by the Environmental Protection Agency’s (EPA or the Agency). Our comments, provided below, contain an Executive Summary, Policy Considerations, Technical Comments, and Conclusions. Should you have any questions or comments, please feel free to contact me at mbasu@croplifeamerica.org or (202) 296-1585.
Sincerely,
Manojit Basu
Managing Director, Science Policy CropLife America
CLA comments on the draft biological evaluations for Atrazine, Simazine, and Propazine
Read the comments.